Educational only — not medical advice.If you’re in crisis or thinking about suicide: call or text 988 (U.S.) or your local emergency number. Support resources.Under construction and review—see the updates log.
Typical dose range: The usual starting dosage is three 0.18 mg tablets (0.54 mg) four times daily during peak withdrawal symptoms, with 5 to 6 hours between doses (label).
Therapeutic drug monitoring not routinely recommended.
Frequency: The usual starting dosage is three 0.18 mg tablets (0.54 mg) four times daily during peak withdrawal symptoms, with 5 to 6 hours between doses (label).
Typical range: The usual starting dosage is three 0.18 mg tablets (0.54 mg) four times daily during peak withdrawal symptoms, with 5 to 6 hours between doses (label).
Mechanism (brief)
Central α2-adrenergic agonist used to mitigate opioid withdrawal symptoms (autonomic hyperactivity, anxiety, GI distress) during abrupt opioid discontinuation; does not treat opioid use disorder itself and does not reduce relapse risk without follow-on care (label/guideline).
Monitor blood pressure and pulse before dosing and in symptomatic patients; adjust/hold dosing for clinically significant hypotension or bradycardia (label/clinical).
Consider ECG monitoring when QT risk factors are present (electrolyte abnormalities, heart failure, bradyarrhythmias, hepatic/renal impairment, or concurrent QT-prolonging drugs such as methadone) (label).
Review sedation, dizziness, and fall risk; reinforce a taper plan to reduce rebound symptoms at discontinuation (label/clinical).